South Rampart Pharma's Technology

South Rampart Pharma is developing a new class of small molecule, non-opioid pain medicines. South Rampart Pharma’s (SRP) proprietary compounds have been effective in reducing both pain and fever in preclinical studies without liver and kidney toxicity that are associated with current common over the counter analgesics. SRP compounds are non-opioid, greatly reducing abuse potential.

View Video Transcript

Despite the high prevalence of acute and chronic pain and its toll on society, there has been no innovation in pain medicines in the past six decades. Current treatment options are limited by a narrow therapeutic index – liver toxicity with acetaminophen, kidney toxicity with NSAIDs, and abuse potential with opioids.  Meeting this need head-on, South Rampart Pharma has created SRP-3D (DA), a novel, highly promising new compound that lacks the liver toxicity of acetaminophen while delivering pain relief and fever reduction. This pain relief innovation occurs via the centrally acting mediator, AM404, that works through endocannabinoid receptors.

SRPs’ safety profile is the result of rational drug design focused on avoiding acetaminophen’s liver toxicity. Acetaminophen is metabolized into NAPQI which, in high doses, is hepatotoxic. In contrast, NAPQI is not produced by SRP-3D (DA) metabolism, avoiding this mechanism of toxicity. SRP-3D (DA)’s safety is also evident in the maintenance of hepatic tight junctions which are disrupted with acetaminophen, and the lack of liver toxicity in animal models even at multi-gram per day doses. In addition, SRP-3D (DA) lacks the kidney toxicity seen with NSAID use and, as a non-narcotic, does not have the opioid abuse potential.   Explore the wealth of SRP-3D (DA) data and learn about investment opportunities in SRP’s pain relief innovation by contacting us at

Using extensive knowledge of drug metabolism, molecular modeling and medicinal chemistry, South Rampart Pharma’s synthesized novel compounds have a unique profile as demonstrated in preclinical models:

Demonstrate both pain and fever reduction
Have no liver toxicity seen with high dose treatment
Show no high-dose or alcohol-associated kidney toxicity
Have favorable liver metabolic profile (cytochrome P450)
Are non-opioid suggesting that they will have significantly reduced abuse potential

Additionally, South Rampart Pharma synthesized these new compounds using derivatives of the active metabolite of a first generation ApAP analgesic and all IND-enabling toxicology studies show a favorable safety profile.

Benefits of South Rampart Pharma’s Technology:

1 target icon

Preclinical results demonstrate SRP compounds have no associated liver toxicity

  • NAPQI (N-acetyl-p-benzoquinone imine) has been identified as the molecule responsible for causing liver damage following high-dose ApAP.
  • Hepatic metabolism of SRP compounds does not lead to the formation of NAPQI which suggests minimal high-dose or chronic use associated liver toxicity.
  • In in vivo preclinical models, toxic doses of ApAP, mimicking inadvertent or intentional overdose, produce obvious gross changes to the liver that are absent in animals equally dosed with SRP lead compounds.
  • Liver cell tight junctions are disrupted with ApAP but maintained with SRPs, demonstrating another manner in which SRPs are not liver toxic.

Hepatotoxicity | Formation of Toxic Free Radicals Absent with SRPs and Present with ApAP Use

Absent Liver Cell Death in High-Dose SRP-Treated Animals, Present in ApAP

2 target icon

Preclinical results demonstrate SRP compounds have minimal kidney toxicity

No rise in creatinine following treatment with high dose SRP compounds.

3 target icon

Preclinical results demonstrate SRP compounds are effective at reducing pain

In three distinct preclinical models of pain, SRP compounds show similar levels of analgesia (pain relief) to ApAP.

ED50 is similar or slightly improved with SRP compounds relative to ApAP.

4 target icon

Preclinical results demonstrate SRP compounds are effective at reducing fever

Lead SRP compounds show similar effectiveness in reducing fever in two different preclinical models of fever compared to ApAP.

SRP compounds are protected by strong intellectual property that cover the synthesis and pharmaceutical composition of the compounds as well as pharmaceutical combinations. Further patent protection will be pursued as necessary to continue coverage of SRP compounds and their use in future indications and formulations.